ExoStat Medical, Inc., located in Prior Lake, Minnesota, and Sensocure, AS, Oslo, Norway, both privately owned companies, jointly announced today that they reached agreement on a long-term technology license agreement relating to an electronic sensor that measures partial pressure COs (pCO2) in oral mucosal tissue. The sensor will constitute an essential component of a new non-invasive device developed to measure tissue hypoperfusion and the possible onset of sepsis. Sepsis is a medical condition that claims millions of lives each year, represents enormous medical expense, and is presently the 10th most frequent cause of death in the U.S. The sensor is part of the MicroStat System and will be owned by ExoStat.
“We are excited to put our patent portfolios and research teams together on this project. We believe, and years of research prove, that early detection of tissue hypoperfusion will save millions of lives and billions of dollars by detecting the possibility of the onset of sepsis, a malady that can cause massive organ failure”, stated Jim Hays, President/CEO of ExoStat Medical. “We feel so strongly about our partnership with Sensocure that we invited Stein Ivar Hansen, Ph.D., Chairman of the Sensocure Board to join our Board of Directors. We were delighted when he accepted.” Dr. Hansen also serves as Managing Director, of MicroTech Innovation, the company responsible for Norwegian Centers of Expertise, micro-and nanotechnologies.
Trond Herje, CEO of Sensocure stated, “We have worked closely with ExoStat for over a year and have determined that we complement one another nicely. Our combined teams have vast experience in sensor medical device development. Critical care and emergency care providers need this device and the data it will provide. We will save many lives through this innovation.”
The resulting measurement from the MicroStat System will provide data necessary for critical care providers to evaluate for possible tissue hypoperfusion, a response to infection in the body, to excessive dehydration/bleeding or to cardiac failure. The two companies hold thirteen approved and/or pending patents on both the science of the measurement and technological design on this compact, robust sensor device. Both ExoStat and Sensocure develop sensors for tissue evaluation and both have FDA approved devices capable of measuring partial pressure CO2 in mucosal tissue.
About ExoStat Medical, Inc.: ExoStat is a privately owned company located in Prior Lake, Minnesota. The technology incorporated in the MicroStat System is proprietary to the company.
About Sensocure, AS: Sensocure is a company based in Norway. Founded in 2011, Sensocure develops and manufactures medical sensor systems. Sensocure has a system called IscAlerttm for early detection of the onset of ischemia by measuring the partial pressure of CO2 in organs. The system is usable for virtually all organs.
Contact:
ExoStat Medical
Jim Hays, President/CEO
jhays@exostatmedical.com
Help employers find you! Check out all the jobs and post your resume.
